#USA #Philadelphia #Immunotherapy #brain cancer #Geneos Therapeutics

Geneos Therapeutics to Present Groundbreaking Findings at SNO Annual Meeting

Geneos Therapeutics, a pioneering biotherapeutics company, is making waves in the field of cancer treatment as it prepares to share its significant findings on personalized DNA immunotherapy for brain cancer at the 31st Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia. The event is slated for November 12-15, 2026, and promises to shed light on the transformative potential of neoantigen-targeted therapies in providing long-term survival for patients diagnosed with aggressive forms of brain cancer.

Key Highlights of the Presentation

The first of the two presentations will highlight the impressive clinical outcomes observed in two patients diagnosed with high-grade gliomas. Following treatments of surgery and radiation, these patients were administered Geneos's innovative neoantigen-targeted personalized DNA immunotherapy, resulting in sustained immunosurveillance and a remarkable progression-free survival exceeding five years since their surgeries. This presentation aims to provide the oncology community with insights into how personalized immunotherapies may enhance the quality of life for patients dealing with formidable cancer diagnoses.

The second presentation will delve deeper into the tumor microenvironment in patients following treatment with this immunotherapy. Understanding these intricate tumor characteristics is crucial for developing future treatment strategies that could lead to even more effective therapies.

Both presentations will be made during the Education Day portion of the conference by esteemed researchers, with Tanner Johanns from Washington University School of Medicine presenting the first poster and Elizabeth A. R. Garfinkle from Nationwide Children's Hospital presenting the second. The focus on characterizing the immune microenvironment represents a significant leap in our understanding of how to tailor cancer treatments to individual patients, further enhancing their chances of survival.

About Geneos Therapeutics

Geneos Therapeutics stands at the forefront of cancer treatment innovation. As a Phase 2 clinical-stage biotherapeutics company, it specializes in developing personalized immunotherapies using its proprietary GT-EPIC™ platform. This platform targets neoantigens—abnormal mutations typically produced by cancer cells—allowing for a focused attack on tumors that are unique to each patient. By harnessing the body’s immune system, Geneos aims to create tailored cancer treatments that deliver not only results but also hope to patients and families affected by cancer.

In a landscape where traditional therapies often fall short, Geneos's approach is refreshing and critically needed. It leverages cutting-edge research and clinical trials to ensure that products entering the market are both effective and safe while also paving the way for the next generation of cancer therapies.

Forward-Looking Statements

As Geneos Therapeutics shares its findings at the SNO Annual Meeting, it is also mindful of the road ahead. The company acknowledges that the journey of developing and commercialization of personalized immunotherapies is fraught with challenges. Their statements reflect optimism regarding the ongoing research and development efforts while emphasizing the commitment to transparency and adherence to regulatory guidelines.

With great anticipation, the oncology community awaits the insights Geneos Therapeutics will present, as they may very well reshape the approach to treating brain cancers in future clinical practices. To find out more about their groundbreaking work, visit Geneos Therapeutics and follow their updates on LinkedIn.